"Poor-risk" germ cell tumors: current progress and future directions.
R J Motzer, D F Bajorin, G J Bosl
Author Information
- R J Motzer: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
No abstract text available.
- CA05826/NCI NIH HHS
- CM57732/NCI NIH HHS
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Bleomycin
Cisplatin
Etoposide
Neoplasms, Germ Cell and Embryonal
Prognosis
Risk Factors
Vinblastine
Biomarkers, Tumor
Bleomycin
Vinblastine
Etoposide
Cisplatin
